Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Palisade Bio, Inc. (PALI) since 2015 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Palisade Bio, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1357459.
Total stock buying since 2015: $358,688.
Total stock sales since 2015: $288,441.
Total stock option exercises since 2015: $1,158,400.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2026 | 5,000 | $9,400 | 0 | $0 | 0 | $0 |
| 2024 | 32,000 | $26,003 | 0 | $0 | 81,682 | $0 |
| 2023 | 50,000 | $28,710 | 300 | $192 | 25,121 | $0 |
| 2022 | 199,331 | $76,056 | 0 | $0 | 0 | $0 |
| 2021 | 32,999 | $88,516 | 0 | $0 | 0 | $0 |
| 2017 | 18,387 | $80,003 | 0 | $0 | 0 | $0 |
| 2016 | 166,189 | $50,000 | 0 | $0 | 19,802 | $0 |
| 2015 | 0 | $0 | 225,000 | $288,249 | 2,416,369 | $1,158,400 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2026-01 | 5,000 | $9,400 | 0 | $0 | 0 | $0 |
| 2024-11 | 0 | $0 | 0 | $0 | 776 | $0 |
| 2024-06 | 0 | $0 | 0 | $0 | 805 | $0 |
| 2024-05 | 2,000 | $9,673 | 0 | $0 | 12,261 | $0 |
| 2024-03 | 0 | $0 | 0 | $0 | 5,558 | $0 |
| 2024-02 | 10,000 | $4,690 | 0 | $0 | 60,973 | $0 |
| 2024-01 | 20,000 | $11,640 | 0 | $0 | 1,309 | $0 |
| 2023-11 | 0 | $0 | 0 | $0 | 8,031 | $0 |
| 2023-10 | 0 | $0 | 0 | $0 | 1,309 | $0 |
| 2023-09 | 50,000 | $28,710 | 300 | $192 | 5,558 | $0 |
| 2023-08 | 0 | $0 | 0 | $0 | 3,475 | $0 |
| 2023-07 | 0 | $0 | 0 | $0 | 1,309 | $0 |
| 2023-06 | 0 | $0 | 0 | $0 | 3,475 | $0 |
| 2023-04 | 0 | $0 | 0 | $0 | 1,964 | $0 |
| 2022-09 | 19,481 | $2,805 | 0 | $0 | 0 | $0 |
| 2022-08 | 147,350 | $36,176 | 0 | $0 | 0 | $0 |
| 2022-03 | 32,500 | $37,075 | 0 | $0 | 0 | $0 |
| 2021-09 | 21,249 | $57,304 | 0 | $0 | 0 | $0 |
| 2021-08 | 11,750 | $31,212 | 0 | $0 | 0 | $0 |
| 2017-05 | 7,500 | $30,000 | 0 | $0 | 0 | $0 |
| 2017-03 | 5,455 | $30,002 | 0 | $0 | 0 | $0 |
| 2017-02 | 2,591 | $10,001 | 0 | $0 | 0 | $0 |
| 2017-01 | 2,841 | $10,000 | 0 | $0 | 0 | $0 |
| 2016-12 | 32,259 | $10,000 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2026-01-09 | Williams Donald Allen | Buy | 5,000 | 1.88 | 9,400 |
| 2024-11-21 | Wei Binxian | Option Ex | 388 | .00 | 0 |
| 2024-11-21 | Williams Donald Allen | Option Ex | 388 | .00 | 0 |
| 2024-06-11 | Wei Binxian | Option Ex | 465 | .00 | 0 |
| 2024-06-11 | Williams Donald Allen | Option Ex | 340 | .00 | 0 |
| 2024-05-28 | Jones Mitchell Lawrence (Chief Medical Officer) | Option Ex | 4,290 | .00 | 0 |
| 2024-05-28 | Finley John David (CEO, CFO, Director) | Option Ex | 7,068 | .00 | 0 |
| 2024-05-28 | Williams Donald Allen | Buy | 1,000 | 4.86 | 4,863 |
| 2024-05-24 | Finley John David (CEO, CFO, Director) | Buy | 1,000 | 4.81 | 4,810 |
| 2024-05-06 | Jones Mitchell Lawrence (CEO, CFO, Director) | Option Ex | 460 | .00 | 0 |
| 2024-05-06 | Finley John David (CEO, CFO, Director) | Option Ex | 443 | .00 | 0 |
| 2024-03-11 | Finley John David (CEO, CFO, Director) | Option Ex | 5,558 | .00 | 0 |
| 2024-02-09 | Neal James R | Option Ex | 10,920 | .00 | 0 |
| 2024-02-08 | Diaz Stephanie | Option Ex | 12,800 | .00 | 0 |
| 2024-02-08 | Trenschel Robert J. | Option Ex | 10,920 | .00 | 0 |
| 2024-02-08 | Csimma Cristina | Option Ex | 12,800 | .00 | 0 |
| 2024-02-06 | Jones Mitchell Lawrence (Chief Medical Officer) | Option Ex | 6,891 | .00 | 0 |
| 2024-02-06 | Finley John David (CEO, CFO, Director) | Buy | 10,000 | .47 | 4,690 |
| 2024-02-06 | Finley John David (CEO, CFO, Director) | Option Ex | 6,642 | .00 | 0 |
| 2024-01-31 | Finley John David (CEO, CFO, Director) | Buy | 10,000 | .56 | 5,590 |
| 2024-01-31 | Williams Donald Allen | Buy | 10,000 | .60 | 6,050 |
| 2024-01-03 | Finley John David (CEO, CFO, Director) | Option Ex | 1,309 | .00 | 0 |
| 2023-11-06 | Jones Mitchell Lawrence (Chief Medical Officer) | Option Ex | 4,556 | .00 | 0 |
| 2023-11-06 | Finley John David (CEO, CFO, Director) | Option Ex | 3,475 | .00 | 0 |
| 2023-10-03 | Finley John David (CEO, CFO, Director) | Option Ex | 1,309 | .00 | 0 |
| 2023-09-27 | Finley John David (CEO, CFO, Director) | Buy | 15,000 | .54 | 8,085 |
| 2023-09-27 | Williams Donald Allen | Buy | 20,000 | .54 | 10,800 |
| 2023-09-14 | Trenschel Robert J. | Sale | 300 | .64 | 192 |
| 2023-09-13 | Finley John David (CEO, CFO, Director) | Buy | 15,000 | .66 | 9,825 |
| 2023-09-11 | Finley John David (CEO, CFO, Director) | Option Ex | 5,558 | .00 | 0 |
| 2023-08-06 | Finley John David (CEO, CFO, Director) | Option Ex | 3,475 | .00 | 0 |
| 2023-07-03 | Finley John David (CEO, CFO, Director) | Option Ex | 1,309 | .00 | 0 |
| 2023-06-12 | Finley John David (CEO, CFO, Director) | Option Ex | 3,475 | .00 | 0 |
| 2023-04-03 | Mcrae Robert Curtis (Chief Operating Officer) | Option Ex | 655 | .00 | 0 |
| 2023-04-03 | Finley John David (CEO, CFO, Director) | Option Ex | 1,309 | .00 | 0 |
| 2022-09-01 | Finley John David (Chief Financial Officer) | Buy | 19,481 | .14 | 2,805 |
| 2022-08-23 | Finley John David (Chief Financial Officer) | Buy | 7,350 | .16 | 1,176 |
| 2022-08-16 | Finley John David (Chief Financial Officer) | Buy | 100,000 | .25 | 25,000 |
| 2022-08-16 | Hallam Thomas (Chief Executive Officer) | Buy | 40,000 | .25 | 10,000 |
| 2022-03-29 | Dawson Michael John (Chief Medical Officer) | Buy | 15,000 | 1.14 | 17,100 |
| 2022-03-28 | Hallam Thomas (Chief Executive Officer) | Buy | 10,000 | 1.18 | 11,800 |
| 2022-03-24 | Finley John David (Chief Financial Officer) | Buy | 7,500 | 1.09 | 8,175 |
| 2021-09-21 | Finley John David (Chief Financial Officer) | Buy | 2,000 | 2.44 | 4,880 |
| 2021-09-21 | Hallam Thomas (Chief Executive Officer) | Buy | 6,000 | 2.49 | 14,940 |
| 2021-09-10 | Trenschel Robert J. (Director) | Buy | 2,142 | 2.98 | 6,383 |
| 2021-09-09 | Trenschel Robert J. (Director) | Buy | 3,400 | 2.89 | 9,826 |
| 2021-09-08 | Trenschel Robert J. (Director) | Buy | 5,000 | 2.75 | 13,750 |
| 2021-09-07 | Trenschel Robert J. (Director) | Buy | 2,707 | 2.78 | 7,525 |
| 2021-08-31 | Trenschel Robert J. (Director) | Buy | 1,750 | 2.75 | 4,812 |
| 2021-08-27 | Finley John David (Chief Financial Officer) | Buy | 10,000 | 2.64 | 26,400 |
| 2017-05-17 | Daly Richard J (Chief Executive Officer) | Buy | 7,500 | 4.00 | 30,000 |
| 2017-03-24 | Lloyd Jones Jonathan Brian (Chief Financial Officer) | Buy | 5,455 | 5.50 | 30,002 |
| 2017-02-24 | Daly Richard J (Chief Executive Officer) | Buy | 2,591 | 3.86 | 10,001 |
| 2017-01-25 | Daly Richard J (Chief Executive Officer) | Buy | 2,841 | 3.52 | 10,000 |
| 2016-12-23 | Daly Richard J (Chief Executive Officer) | Buy | 32,259 | .31 | 10,000 |
| 2016-11-25 | Daly Richard J (Chief Executive Officer) | Buy | 35,715 | .28 | 10,000 |
| 2016-10-25 | Daly Richard J (Chief Executive Officer) | Buy | 35,715 | .28 | 10,000 |
| 2016-09-23 | Daly Richard J (Chief Executive Officer) | Buy | 31,250 | .32 | 10,000 |
| 2016-09-23 | Lloyd Jones Jonathan Brian (Chief Financial Officer) | Buy | 31,250 | .32 | 10,000 |
| 2016-01-27 | Garr Richard (CEO) | Option Ex | 19,802 | .00 | 0 |
| 2015-11-19 | Oldaker William Clyde | Option Ex | 15,000 | .00 | 0 |
| 2015-11-19 | Garr Richard (CEO) | Option Ex | 138,122 | .00 | 0 |
| 2015-11-19 | Johe Karl (Chief Scientific Officer) | Option Ex | 143,247 | .00 | 0 |
| 2015-11-16 | Johe Karl (Chief Scientific Officer) | Sale | 25,000 | 1.09 | 27,250 |
| 2015-11-09 | Johe Karl (Chief Scientific Officer) | Sale | 25,000 | 1.18 | 29,500 |
| 2015-11-02 | Johe Karl (Chief Scientific Officer) | Sale | 25,000 | 1.17 | 29,350 |
| 2015-10-26 | Johe Karl (Chief Scientific Officer) | Sale | 25,000 | 1.13 | 28,199 |
| 2015-10-19 | Johe Karl (Chief Scientific Officer) | Sale | 25,000 | 1.23 | 30,700 |
| 2015-10-12 | Johe Karl (Chief Scientific Officer) | Sale | 25,000 | 1.31 | 32,725 |
| 2015-10-05 | Johe Karl (Chief Scientific Officer) | Sale | 25,000 | 1.26 | 31,450 |
| 2015-09-28 | Johe Karl (Chief Scientific Officer) | Sale | 25,000 | 1.64 | 41,000 |
| 2015-09-21 | Johe Karl (Chief Scientific Officer) | Sale | 25,000 | 1.52 | 38,075 |
| 2015-07-24 | Garr Richard (CEO) | Option Ex | 800,000 | .50 | 400,000 |
| 2015-07-22 | Johe Karl (Chief Scientific Officer) | Option Ex | 1,200,000 | .50 | 600,000 |
| 2015-05-27 | Oldaker William Clyde | Option Ex | 60,000 | 1.32 | 79,200 |
| 2015-05-22 | Ogilvie Scott Varde | Option Ex | 60,000 | 1.32 | 79,200 |
Insider trading activities including stock purchases, stock sales, and option exercises of PALI listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Palisade Bio, Inc. (symbol PALI, CIK number 1357459) see the Securities and Exchange Commission (SEC) website.